Sera Prognostics, Inc
Sera Prognostics, Inc. is a U.S.-based life sciences company focused on maternal health diagnostics. Its core product is the PreTRM test, a proteomic blood test designed to assess the risk of preterm birth, with additional pipeline tests and related services under development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBlood-based proteomic testing used to assess preterm birth risk in pregnant patients.
Additional maternal-health and related tests under development for future commercialization.
Supporting services tied to test ordering, specimen collection, shipping, and processing.
Customers
Sera sells primarily to health plans, payers, and health systems that can authorize or reimburse use of the PreTRM test. The test is ultimately used in the care pathway for pregnant patients, so adoption depends on physicians, clinicians, and payer coverage decisions. The company also relies on a limited number of direct customers, making customer concentration an important feature of the business model.
Buy access to PreTRM to support coverage decisions and population health management.
Order the test for eligible patients and integrate it into obstetric workflows.
Large customers such as Elevance Health that can account for a significant share of revenue.
Use test results to guide monitoring and intervention decisions.
Strategy
The company’s strategy is to expand adoption of the PreTRM test through payer engagement, clinical evidence, and broader commercialization capabilities. It also seeks partnerships and other strategic options for PreTRM and future product candidates while building a pipeline beyond its initial test. Evidence generation, including published study data, is central to supporting market acceptance and reimbursement.
Revenue depends on converting clinical evidence into routine test ordering and reimbursement.
Clinical data supports market acceptance, guideline inclusion, and payer coverage.
Future growth depends on more than one diagnostic product.
Geography
Sera Prognostics is headquartered in the United States and operates as a U.S. clinical diagnostics company. Its testing, commercialization, and regulatory activities are centered in the U.S., with potential expansion into foreign jurisdictions as the company seeks broader utilization of PreTRM. Geography matters because laboratory licensing, payer adoption, and clinical practice patterns can differ by state and country.
Risks
Sera is exposed to commercialization risk because its revenue depends heavily on adoption of a single core test and a small number of customers. It also faces clinical, regulatory, operational, and funding risks typical of an early-stage diagnostics company, including laboratory uptime, specimen logistics, and the need to raise capital to support development and commercialization.
- Dependence on PreTRM adoptionImpact: HighLikelihood: High
Substantially all near-term revenue is expected to come from one test, so weak market acceptance would directly reduce sales.
Exposure: PreTRM test commercialization
- Funding and liquidity pressureImpact: HighLikelihood: High
The company expects continued operating losses and may need additional capital to fund commercialization and R&D.
Exposure: Operating cash burn
- Customer concentrationImpact: HighLikelihood: Medium
A limited number of direct customers, including Elevance Health, may account for a significant share of revenue and cash flow.
Exposure: Direct customer contracts
- Laboratory and specimen logistics disruptionImpact: HighLikelihood: Low
Testing depends on a CLIA-certified lab plus third-party specimen collection and courier services.
Exposure: Lab operations and logistics
- Commercial execution riskImpact: MediumLikelihood: High
The company has limited sales and marketing experience and must build specialized commercialization capabilities.
Exposure - Competitive and clinical adoption riskImpact: MediumLikelihood: High
Competing diagnostics or unfavorable clinical evidence could limit adoption by providers and payers.
Exposure: Molecular diagnostics and proteomics market
Accounting
Judgemental itemsReported revenue depends on when tests are ordered, performed, and reimbursed under customer arrangements.
Impact: Can create timing differences between commercial traction and recognized revenue
A small customer base and early-stage commercialization can cause uneven period-to-period results.
Impact: Makes trend analysis and comparability more difficult
Equity awards are common in development-stage life sciences companies and affect operating expenses.
Impact: Can materially influence reported losses
Any acquired or capitalized intangible assets require judgment about recoverability and fair value.
Impact: Could lead to non-cash charges if assumptions weaken
Similar listed companies
Publicly listed companies with a comparable business focus.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Seer, Inc.
SEER · Laboratory Analytical Instruments
Damora Therapeutics, Inc.
DMRA · Pharmaceutical Preparations
Last updated: 24/09/2026